Suchergebnisse - "Zhou, Jianying"

PubPharm (31)

1

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6) : single-arm, open-label, multicentre, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2024

von Wang, M. | Fan, Y. | Sun, M. | +37

2

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

3

Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study : a case report

enthalten in: Anti-cancer drugs | 2023

von Wu, L. | Cheng, Y. | Huang, D. | +7

4

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

5

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification : INSIGHT Final Analysis

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Liam, C. | Ahmad, A. | Hsia, T. | +13

6

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer : a pooled analysis from two phase 2 studies

enthalten in: BMC medicine | 2023

von Hu, X. | Zhang, S. | Ma, Z. | +27

7

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

8

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy : A Phase 2, Multicenter, Single-Arm, Open-Label Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Lu, S. | Zhang, Y. | Zhang, G. | +52

9

AENEAS : A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Lu, S. | Dong, X. | Jian, H. | +56

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3103-3105. - PMID 35679530

10

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

enthalten in: Cancer discovery | 2022

von Wang, M. | Yang, J. | Mitchell, P. | +22